New MRI Breakthrough Can Detect Tiny Lung Tumors Before They Spread

A novel class of protein-based MRI contrast agents has demonstrated the ability to identify invasive lung cancer and metastatic spread at significantly earlier stages than current clinical imaging standards. The study, published in Science Advances, details a precision diagnostic method capable of pinpointing tumors and secondary lesions as small as 1 millimeter.

Targeting the Tumor Microenvironment

The research focuses on a protein-based agent dubbed hProCA32.Collagen, which is engineered to home in on collagen type I. This structural protein is found in significantly elevated concentrations within the microenvironment of aggressive lung tumors and metastatic sites. By binding to these markers, the agent allows clinicians to visualize not only the presence of a tumor but also its biological characteristics related to invasiveness and growth potential.

According to Jenny J. Yang, a professor emerita at Georgia State University and co-leader of the study, this molecular imaging approach offers a significant upgrade over traditional methods. By visualizing the remodeling of collagen, the technology provides critical insights into how aggressively a cancer may behave, which could potentially reduce the reliance on invasive surgical biopsies.

Advancing Precision Oncology

The imaging technique proved particularly effective in identifying aggressive lung adenocarcinomas, a subtype often characterized by mutations that drive therapy resistance and rapid metastasis. In preclinical models, the contrast agent successfully mapped tumors and metastases throughout the adrenal glands, kidneys, and lungs without the exposure to ionizing radiation associated with other screening methods.

The development of this technology was a multi-institutional effort involving Georgia State University, Emory University, and the University of Alabama at Birmingham (UAB). The team utilized Georgia State’s Advanced Translational Imaging Facility to conduct the imaging studies, while researchers at the Winship Cancer Institute at Emory provided essential cancer models and biological expertise. Wei Zhou of Emory University served as co-corresponding author alongside Yang.

Clinical Potential and Future Directions

Beyond early detection, the researchers suggest this technology could play a transformative role in personalized cancer care. By monitoring collagen changes in real time, physicians may be better equipped to identify high-risk patients, tailor treatment plans, and track how well a patient is responding to a specific therapy.

“This is a game changer for cancer diagnosis and precision medicine,” Yang noted. “For the first time, we’ve shown that precision MRI can detect tiny tumors and whole body metastases without using harmful radiation.”

The path toward clinical implementation is already underway. InLighta Biosciences, a biotechnology firm established by Yang that holds licensed intellectual property from Georgia State, is currently advancing the agent toward human trials. With partial support from the National Institutes of Health, including Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants, the team is preparing an investigational new drug (IND) application for submission to the U.S. Food and Drug Administration.